Cysteine cathepsins: Multifunctional enzymes in cancer

Nature Reviews Cancer

Volumn 6, Issue 10, 2006, Pages 764-775

  Mohamed, Mona Mostafa ^a,b   Sloane, Bonnie F ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN; CATHEPSIN B; CATHEPSIN H; CATHEPSIN K; CATHEPSIN L; CATHEPSIN O; CATHEPSIN S; CATHEPSIN V; CATHEPSIN W; CATHEPSIN X; CYSTATIN C; CYSTATIN D; CYSTATIN E; CYSTATIN F; CYSTATIN M; CYSTATIN S; CYSTATIN SA; CYSTEINE; DIPEPTIDYL PEPTIDASE I; KININOGEN; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER GROWTH; CANCER INVASION; CELL MIGRATION; CELL SURFACE; CONFERENCE PAPER; CYSTATIN SN; DOWN REGULATION; GENE AMPLIFICATION; HUMAN; LYSOSOME; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN SECRETION; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; TUMOR CELL; TUMOR GROWTH;

CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; HUMANS; NEOPLASMS;

EID: 33749017931     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1949     Document Type: Conference Paper

References (145)

1. Rawlings, N. D., Morton, F. R. & Barrett, A. J. MEROPS: the peptidase database. Nucleic Acids Res. 34, D270-D272 (2006). This paper describes an excellent comprehensive database for proteases and protease inhibitors.
2. McCawley, L. J. & Matrisian, L. M. Matrix metalloproteinases: they're not just for matrix anymore! Curr. Opin. Cell Biol. 13, 534-540 (2001).
3. Egeblad, M. & Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev. Cancer 2, 161-174 (2002).
4. Lynch, C. C. & Matrisian, L. M. Matrix metalloproteinases in tumor-host cell communication. Differentiation 70, 561-573 (2002).
5. Mott, J. D. & Werb, Z. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 16, 558-564 (2004).
6. Balbin, M. et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nature Genet. 35, 252-257 (2003).
7. Harbeck, N. et al. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin. Breast Cancer 5, 348-352 (2004).
8. Obiezu, C. V. & Diamandis, E. P. Human tissue kallikrein gene family: applications in cancer. Cancer Lett. 224, 1-22 (2005).
9. List, K. et al. Deregulated matriptase causes Ras-independent multistage carcinogenesis and promotes Ras-mediated malignant transformation. Genes Dev. 19, 1934-1950 (2005).
10. Sajid, M. & McKerrow, J. H. Cysteine proteases of parasitic organisms. Mol. Biochem. Parasitol. 120, 1-21 (2002).
11. McKerrow, J. H. Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: insights on safety, target validation, and mechanism of action. Int. J. Parasitol. 29, 833-837 (1999).
12. Saftig, P. et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl Acad. Sci. USA 95, 13453-13458 (1998).
13. Shi, G. P. et al. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity 10, 197-206 (1999).
14. Roth, W. et al. Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling. FASEB J. 14, 2075-2086 (2000).
15. Stypmann, J. et al. Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc. Natl Acad. Sci. USA 99, 6234-6239 (2002).
16. Reinheckel, T., Deussing, J., Roth, W. & Peters, C. Towards specific functions of lysosomal cysteine peptidases: phenotypes of mice deficient for cathepsin B or cathepsin L. Biol. Chem. 382, 735-741 (2001).
17. Driessen, C., Lennon-Dumenil, A. M. & Ploegh, H. L. Individual cathepsins degrade immune complexes internalized by antigen-presenting cells via Fcγ receptors. Eur. J. Immunol. 31, 1592-1601 (2001).
18. Felbor, U. et al. Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc. Natl Acad. Sci. USA 99, 7883-7888 (2002).
19. Pham, C. T., Ivanovich, J. L., Raptis, S. Z., Zehnbauer, B. & Ley, T. J. Papillon-Lefevre syndrome: correlating the molecular, cellular, and clinical consequences of cathepsin C/dipeptidyl peptidase I deficiency in humans. J. Immunol. 173, 7277-7281 (2004).
20. Pham, C. T. & Ley, T. J. Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc. Natl Acad. Sci. USA 96, 8627-8632 (1999).
21. Caughey, G. H. New developments in the genetics and activation of mast cell proteases. Mol. Immunol. 38, 1353-1357 (2002).
22. Xia, L. et al. Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones. Biol. Chem. 380, 679-687 (1999).
23. Friedrichs, B. et al. Thyroid functions of mouse cathepsins B, K, and L. J. Clin. Invest. 111, 1733-1745 (2003).
24. Hughes, S. J. et al. A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma. Proc. Natl Acad. Sci. USA 95, 12410-12415 (1998).
25. Lin, L. et al. A minimal critical region of the 8p22-23 amplicon in esophageal adenocarcinomas defined using sequence tagged site-amplification mapping and quantitative polymerase chain reaction includes the GATA-4 gene. Cancer Res. 60, 1341-1347 (2000).
26. Berquin, I. M., Cao, L., Fong, D. & Sloane, B. F. Identification of two new exons and multiple transcription start points in the 5′-untranslated region of the human cathepsin-B-encoding gene. Gene 159, 143-149 (1995).
27. Seth, P., Mahajan, V. S. & Chauhan, S. S. Transcription of human cathepsin L mRNA species hCATL B from a novel alternative promoter in the first intron of its gene. Gene 321, 83-91 (2003).
28. Arora, S. & Chauhan, S. S. Identification and characterization of a novel human cathepsin L splice variant. Gene 293, 123-131 (2002).
29. Yan, S. & Sloane, B. F. Molecular regulation of human cathepsin B: implication in pathologies. Biol. Chem. 384, 845-854 (2003).
30. Gong, Q., Chan, S. J., Bajkowski, A. S., Steiner, D. F. & Frankfater, A. Characterization of the cathepsin B gene and multiple mRNAs in human tissues: evidence for alternative splicing of cathepsin B pre-mRNA. DNA Cell Biol. 12, 299-309 (1993). References 24 and 26-30 describe the molecular mechanisms (amplification, alternative promoters and alternative splicing) that result in increased expression of the cysteine cathepsins B and L in cancer.
31. Zwicky, R., Muntener, K., Csucs, G., Goldring, M. B. & Baici, A. Exploring the role of 5′ alternative splicing and of the 3′-untranslated region of cathepsin B mRNA. Biol. Chem. 384, 1007-1018 (2003).
32. Hizel, C. et al. Evaluation of the 5′ spliced form of human cathepsin B mRNA in colorectal mucosa and tumors. Oncol. Rep. 5, 31-34 (1998).
33. Berquin, I. M., Ahram, M. & Sloane, B. F. Exon 2 of human cathepsin B derives from an Alu element. FEBS Lett. 419, 121-123 (1997).
34. Landry, J. R., Medstrand, P. & Mager, D. L. Repetitive elements in the 5′ untranslated region of a human zinc-finger gene modulate transcription and translation efficiency. Genomics 76, 110-116 (2001).
35. Baici, A., Montener, K., Willimann, A. & Zwicky, R. Regulation of human cathepsin B by alternative mRNA splicing: homeostasis, fatal errors and cell death. Biol. Chem. 387, 1017-1021 (2006).
36. Rao, J. S. Molecular mechanisms of glioma invasiveness: the role of proteases. Nature Rev. Cancer 3, 489-501 (2003).
37. Yan, S., Berquin, I. M., Troen, B. R. & Sloane, B. F. Transcription of human cathepsin B is mediated by Sp1 and Ets family factors in glioma. DNA Cell. Biol. 19, 79-91 (2000).
38. Konduri, S. et al. Elevated levels of cathepsin B in human glioblastoma cell lines. Int. J. Oncol. 19, 519-524 (2001).
39. Szpaderska, A. M., Silberman, S., Ahmed, Y. & Frankfater, A. Sp1 regulates cathepsin B transcription and invasiveness in murine B16 melanoma cells. Anticancer Res. 24, 3887-3891 (2004).
40. Jean, D., Guillaume, N. & Frade, R. Characterization of human cathepsin L promoter and identification of binding sites for NF-Y, Sp1 and Sp3 that are essential for its activity. Biochem J. 361, 173-184 (2002).
41. Jean, D., Rousselet, N. & Frade, R. Expression of cathepsin L in human tumor cells is under the control of distinct regulatory mechanisms. Oncogene 25, 1474-1784 (2006).
42. Deussing, J., von Olshausen, I. & Peters, C. Murine and human cathepsin Z: cDNA-cloning, characterization of the genes and chromosomal localization. Biochim. Biophys. Acta 1491, 93-106 (2000).
43. Shi, G. P. et al. Human cathepsin S: chromosomal localization, gene structure, and tissue distribution. J. Biol. Chem. 269, 11530-11536 (1994).
44. Rao, N. V., Rao, G. V. & Hoidal, J. R. Human dipeptidyl-peptidase I. Gene characterization, localization, and expression. J. Biol. Chem. 272, 10260-10265 (1997).
45. Dittmer, J. The biology of the Ets1 proto-oncogene. Mol. Cancer 2, 2-29 (2003).
46. Yoneda, T. & Hiraga, T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem. Biophys. Res. Commun. 328, 679-687 (2005).
47. Condeelis, J. & Pollard, J. W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124, 263-266 (2006).
48. Matsumoto, M. et al. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J. Biol. Chem. 279, 45969-45979 (2004).
49. Tamura, T., Thotakura, P., Tanaka, T. S., Ko, M. S. & Ozato, K. Identification of target genes and a unique cis element regulated by IRF-8 in developing macrophages. Blood 106, 1938-1947 (2005).
50. Berquin, I. M. et al. Differentiating agents regulate cathepsin B gene expression in HL-60 cells. J. Leukoc. Biol. 66, 609-616 (1999).
51. Campo, E. et al. Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am. J. Pathol. 145, 301-309 (1994).
52. Vasiljeva, O. et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res. 66, 5242-5250 (2006). Shows that cathepsin B expressed by tumour cells and macrophages is functionally involved in malignant progression and metastasis of mammary cancers in MMTV-PyMT transgenic mice.
53. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004). Identifies cathepsin V (L2) as part of a two-gene invasion signature for predicting the recurrence of breast cancer.
54. Santamaria, I. et al. Cathepsin L2, a novel human cysteine proteinase produced by breast and colorectal carcinomas. Cancer Res. 58, 1624-1630 (1998).
55. Haider, A. S. et al. Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. J. Invest. Dermatol. 126, 869-881 (2006).
56. Linnerth, N. M., Sirbovan, K. & Moorehead, R. A. Use of a transgenic mouse model to identify markers of human lung tumors. Int. J. Cancer 114, 977-982 (2005).
57. Fernandez, P. L. et al. Expression of cathepsins B and S in the progression of prostate carcinoma. Int. J. Cancer 95, 51-55 (2001).
58. Nagler, D. K. et al. Up-regulation of cathepsin X in prostate cancer and prostatic intraepithelial neoplasia. Prostate 60, 109-119 (2004).
59. Allinen, M. et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6, 17-32 (2004).
60. Flannery, T. et al. The clinical significance of cathepsin S expression in human astrocytomas. Am. J. Pathol. 163, 175-182 (2003).
61. Mikkelsen, T. et al. Immunolocalization of cathepsin B in human glioma: implications for tumor invasion and angiogenesis. J. Neurosurg. 83, 285-290 (1995).
62. Buck, M. R., Karustis, D. G., Day, N. A., Honn, K. V. & Sloane, B. F. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J. 282, 273-278 (1992).
63. Ishidoh, K. & Kominami, E. Procathepsin L degrades extracellular matrix proteins in the presence of glycosaminoglycans in vitro. Biochem. Biophys. Res. Commun. 217, 624-631 (1995).
64. Mai, J., Sameni, M., Mikkelsen, T. & Sloane, B. F. Degradation of extracellular matrix protein tenascin-C by cathepsin B: an interaction involved in the progression of gliomas. Biol. Chem. 383, 1407-1413 (2002).
65. Gocheva, V. et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 20, 543-556 (2006). Shows that the cysteine cathepsins B, L and S, but not C, are functionally involved in invasion, angiogenesis, resistance to apoptosis and proliferation of pancreatic cancers in RIP1-Tag2 transgenic mice.
66. Kobayashi, H. et al. Effects of membrane-associated cathepsin B on the activation of receptor-bound prourokinase and subsequent invasion of reconstituted basement membranes. Biochim. Biophys. Acta 1178, 55-62 (1993).
67. Guo, M., Mathieu, P. A., Linebaugh, B., Sloane, B. F. & Reiners, J. J. Jr. Phorbol ester activation of a proteolytic cascade capable of activating latent transforming growth factor-βL a process initiated by the exocytosis of cathepsin B. J. Biol. Chem. 277, 14829-14837 (2002). References 66 and 67 provide evidence for the participation of secreted and membrane-associated cysteine cathepsin B in proteolytic networks on the tumour cell surface.
68. Behrendt, N. The urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodeling. Biol. Chem. 385, 103-136 (2004).
69. Curino, A. C. et al. Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy. J. Cell Biol. 169, 977-985 (2005). Shows that uPARAP expressed by tumour-associated fibroblasts is the functional link to collagen degradation by intracellular cysteine cathepsins in mammary cancer in MMTV-PyMT transgenic mice.
70. Cavallo-Medved, D. & Sloane, B. F. Cell-surface cathepsin B: understanding its functional significance. Curr. Top. Dev. Biol. 54, 313-341 (2003).
71. Podosomes - invadopodia - focal adhesions. Zellbiologie Aktuell [online], http://www.zellbiologie.de/ journal/artikel/16_3_2005.pdf (2005).
72. Delaguillaumie, A. et al. Tetraspanin CD82 controls the association of cholesterol-dependent microdomains with the actin cytoskeleton in T lymphocytes: relevance to co-stimulation. J. Cell Sci. 117, 5269-5282 (2004).
73. Zilber, M. T. et al. MHC class II/CD38/CD9: a lipid-raft-dependent signaling complex in human monocytes. Blood 106, 3074-3081 (2005).
74. Cherukuri, A. et al. B cell signaling is regulated by induced palmitoylation of CD81. J. Biol. Chem. 279, 31973-31982 (2004).
75. Cavallo-Medved, D., Mai, J., Dosescu, J., Sameni, M. & Sloane, B. F. Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. J. Cell Sci. 118, 1493-1503 (2005).
76. Mai, J., Finley, R. L. Jr, Waisman, D. M. & Sloane, B. F. Human procathepsin B interacts with the annexin II tetramer on the surface of tumor cells. J. Biol. Chem. 275, 12806-12812 (2000). Identifies a tumour cell-surface binding partner for a cysteine cathepsin, cathepsin B.
77. Gerke, V. & Moss, S. E. Annexins: from structure to function. Physiol. Rev. 82, 331-371 (2002).
78. Mayran, N., Parton, R. G. & Gruenberg, J. Annexin II regulates multivesicular endosome biogenesis in the degradation pathway of animal cells. EMBO J. 22, 3242-3253 (2003).
79. Collette, J. et al. Biosynthesis and alternate targeting of the lysosomal cysteine protease cathepsin L. Int. Rev. Cytol. 241, 1-51 (2004).
80. Ulbricht, B. et al. Influence of 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE) on the localization of cathepsin B and cathepsin L in human lung tumor cells. Eur. J. Cell Biol. 74, 294-301 (1997).
81. Cougoule, C. et al. Activation of the lysosome-associated p61Hck isoform triggers the biogenesis of podosomes. Traffic 6, 682-694 (2005).
82. MacLeod, T. J., Kwon, M., Filipenko, N. R. & Waisman, D. M. Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits: characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin. J. Biol. Chem. 278, 25577-25584 (2003).
83. Uittenbogaard, A., Everson, W. V., Matveev, S. V. & Smart, E. J. Cholesteryl ester is transported from caveolae to internal membranes as part of a caveolinannexin II lipid-protein complex. J. Biol. Chem. 277, 4925-4931 (2002).
84. Stahl, A. & Mueller, B. M. The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J. Cell Biol. 129, 335-344 (1995).
85. Schwab, W. et al. Expression of the urokinase-type plasminogen activator receptor in human articular chondrocytes: association with caveolin and β1-integrin. Histochem. Cell Biol. 115, 317-323 (2001).
86. Bass, R. et al. Regulation of urokinase receptor proteolytic function by the tetraspanin CD82. J. Biol. Chem. 280, 14811-14818 (2006).
87. Sridhar, S. C. & Miranti, C. K. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene 25, 2367-2378 (2006).
88. Hauck, C. R., Hsia, D. A., Puente, X. S., Cheresh, D. A. & Schlaepfer, D. D. FRNK blocks v-Src-stimulated invasion and experimental metastases without effects on cell motility or growth. EMBO J. 21, 6289-6302 (2002).
89. Roshy, S., Sloane, B. F. & Moin, K. Pericellular cathepsin B and malignant progression. Cancer Metastasis Rev. 22, 271-286 (2003).
90. Vollenweider, F., Kappeler, F., Itin, C. & Hauri, H. P. Mistargeting of the lectin ERGIC-53 to the endoplasmic reticulum of HeLa cells impairs the secretion of a lysosomal enzyme. J. Cell Biol. 142, 377-389 (1998).
91. Appenzeller, C., Andersson, H., Kappeler, F. & Hauri, H. P. The lectin ERGIC-53 is a cargo transport receptor for glycoproteins. Nature Cell Biol. 1, 330-334 (1999).
92. Podgorski, I. et al. Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer. Neoplasia 7, 207-223 (2005).
93. Cavallo-Medved, D. et al. Mutant K-ras regulates cathepsin B localization on the surface of human colorectal carcinoma cells. Neoplasia 5, 507-519 (2003). Localizes the cysteine cathepsin B to caveolar membrane microdomains in colon cancer.
94. Waghray, A., Keppler, D., Sloane, B. F., Schuger, L. & Chen, Y. Q. Analysis of a truncated form of cathepsin H in human prostate tumor cells. J. Biol. Chem. 277, 11533-11538 (2002).
95. Reddy, V. Y., Zhang, Q. Y. & Weiss, S. J. Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. Proc. Natl Acad. Sci. USA 92, 3849-3853 (1995).
96. Punturieri, A. et al. Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages. J. Exp. Med. 192, 789-799 (2000).
97. Rozhin, J., Sameni, M., Ziegler, G. & Sloane, B. F. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res. 54, 6517-6525 (1994).
98. Honn, K. V. et al. A lipoxygenase metabolite, 12-(S)-HETE, stimulates protein kinase C-mediated release of cathepsin B from malignant cells. Exp. Cell Res. 214, 120-130 (1994).
99. Schraufstatter, I. U. et al. IL-8-mediated cell migration in endothelial cells depends on cathepsin B activity and transactivation of the epidermal growth factor receptor. J. Immunol. 171, 6714-6722 (2003).
100. Gatenby, R. A., Gawlinski, E. T., Gmitro, A. F., Kaylor, B. & Gillies, R. J. Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res. 66, 5216-5223 (2006).
101. Mueller, M. M. & Fusenig, N. E. Friends or foes-bipolar effects of the tumour stroma in cancer. Nature Rev. Cancer 4, 839-849 (2004).
102. Nishimura, Y., Itoh, K., Yoshioka, K., Uehata, M. & Himeno, M. Small guanosine triphosphatase Rho/Rho-associated kinase as a novel regulator of intracellular redistribution of lysosomes in invasive tumor cells. Cell Tissue Res. 301, 341-351 (2000).
103. Nishimura, Y., Itoh, K., Yoshioka, K., Tokuda, K. & Himeno, M. Overexpression of ROCK in human breast cancer cells: evidence that ROCK activity mediates intracellular membrane traffic of lysosomes. Pathol. Oncol. Res. 9, 83-95 (2003).
104. Nishimura, Y., Yoshioka, K., Bernard, O., Himeno, M. & Itoh, K. LIM kinase 1: evidence for a role in the regulation of intracellular vesicle trafficking of lysosomes and endosomes in human breast cancer cells. Eur. J. Cell Biol. 83, 369-380 (2004).
105. Alblas, J., Ulfman, L., Hordijk, P. & Koenderman, L. Activation of Rhoa and ROCK are essential for detachment of migrating leukocytes. Mol. Biol. Cell 12, 2137-2145 (2001).
106. Almeida, P. C. et al. Cathepsin B activity regulation. Heparin-like glycosaminogylcans protect human cathepsin B from alkaline pH-induced inactivation. J. Biol. Chem. 276, 944-951 (2001).
107. Nascimento, F. D. et al. Cathepsin X binds to cell surface heparan sulfate proteoglycans. Arch. Biochem. Biophys. 436, 323-332 (2005).
108. Sameni, M., Moin, K. & Sloane, B. F. Imaging proteolysis by living human breast cancer cells. Neoplasia 2, 496-504 (2000).
109. East, L. & Isacke, C. M. The mannose receptor family. Biochim. Biophys. Acta 1572, 364-386 (2002).
110. Sameni, M., Dosescu, J., Moin, K. & Sloane, B. F. Functional imaging of proteolysis: stromal and inflammatory cells increase tumor proteolysis. Mol. Imaging 2, 159-175 (2003).
111. Sokol, J. P. & Schiemann, W. P. Cystatin C antagonizes transforming growth factor beta signaling in normal and cancer cells. Mol. Cancer Res. 2, 183-195 (2004).
112. Kopitz, C., Anton, M., Gansbacher, B. & Kruger, A. Reduction of experimental human fibrosarcoma lung metastasis in mice by adenovirus-mediated cystatin C overexpression in the host. Cancer Res. 65, 8608-8612 (2005).
113. Zhang, J. et al. Cystatin M: a novel candidate tumor suppressor gene for breast cancer. Cancer Res. 64, 6957-6964 (2004).
114. Li, W. et al. Overexpression of stefin A in human esophageal squamous cell carcinoma cells inhibits tumor cell growth, angiogenesis, invasion, and metastasis. Clin. Cancer Res. 11, 8753-8762 (2005).
115. Vigneswaran, N. et al. Silencing of cystatin M in metastatic oral cancer cell line MDA-686Ln by siRNA increases cysteine proteinases and legumain activities, cell proliferation and in vitro invasion. Life Sci. 78, 898-907 (2006).
116. Wang, B. et al. Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J. Biol. Chem. (2005). Shows that cathepsin S expressed by tumour cells is functionally involved in the induction of angiogenesis associated with pancreatic cancer in RIP1-Tag2 transgenic mice.
117. Jedeszko, C. & Sloane, B. F. Cysteine cathepsins in human cancer. Biol. Chem. 385, 1017-1027 (2004).
118. Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392 (2002).
119. Joyce, J. A. et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5, 443-453 (2004). Shows that pharmacological knockdown of cysteine cathepsins reduces progression of pancreatic cancer in RIP1-Tag2 transgenic mice.
120. Bergers, G., Javaherian, K., Lo, K. M., Folkman, J. & Hanahan, D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808-812 (1999).
121. Krueger, S., Haeckel, C., Buehling, F. & Roessner, A. Inhibitory effects of antisense cathepsin B cDNA transfection on invasion and motility in a human osteosarcoma cell line. Cancer Res. 59, 6010-6014 (1999).
122. Mohanam, S. et al. Down-regulation of cathepsin B expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 20, 3665-3673 (2001).
123. Krueger, S., Kellner, U., Buehling, F. & Roessner, A. Cathepsin L antisense oligonucleotides in a human osteosarcoma cell line: effects on the invasive phenotype. Cancer Gene Ther. 8, 522-528 (2001).
124. Krueger, S. et al. Up-regulation of cathepsin X in Helicobacter pylori gastritis and gastric cancer. J. Pathol. 207, 32-42 (2005).
125. Sloane, B. F. et al. Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment. Semin. Cancer Biol. 15, 149-157 (2005).
126. Kroemer, G. & Jaattela, M. Lysosomes and autophagy in cell death control. Nature Rev. Cancer 5, 886-897 (2005).
127. Yanamandra, N. et al. Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis. Oncogene 23, 2224-2230 (2004).
128. Coussens, L. M., Hanahan, D. & Arbeit, J. M. Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am. J. Pathol. 149, 1899-1917 (1996).
129. Overall, C. M. & Kleifeld, O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br. J. Cancer 94, 941-946 (2006).
130. Urbich, C. et al. Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nature Med. 11, 206-213 (2005).
131. Sloane, B. F., Sameni, M., Podgorski, I., Cavallo-Medved, D. & Moin, K. Functional imaging of tumor proteolysis. Annu. Rev. Pharmacol. Toxicol. 46, 301-315 (2006).
132. Moin, K., McIntyre, J. O., Matrisian, L. M. & Sloane, B. F. in In Vivo Imaging of Cancer Therapy (eds Shields, A. & Price, P.) (Humana Press, New Jersey, in the press).
133. Panchal, R. G., Cusack, E., Cheley, S. & Bayley, H. Tumor protease-activated, pore-forming toxins from a combinatorial library. Nature Biotechnol. 14, 852-856 (1996).
134. Potrich, C. et al. Cytotoxic activity of a tumor protease-activated pore-forming toxin. Bioconjug. Chem. 16, 369-376 (2005).
135. Bien, S. et al. Influence of doxorubicin on gene expression and protein pattern in HeLa cells. Int. J. Clin. Pharmacol. Ther. 42, 640-641 (2004).
136. + tumors. Cancer Res. 63, 5526-5531 (2003).
137. Satchi-Fainaro, R. et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nature Med. 10, 255-261 (2004).
138. Vicent, M. J. & Duncan, R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol. 24, 39-47 (2006).
139. Lakka, S. S. et al. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 23, 4681-4689 (2004).
140. Gondi, C. S. et al. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 23, 8486-8496 (2004).
141. Musil, D. et al. The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. EMBO J. 10, 2321-2330 (1991).
142. Alvarez-Fernandez, M. et al. Inhibition of mammalian legumain by some cystatins is due to a novel second reactive site. J. Biol. Chem. 274, 19195-19203 (1999).
143. Zeeuwen, P. L. et al. Evidence that unrestricted legumain activity is involved in disturbed epidermal cornification in cystatin M/E deficient mice. Hum. Mol. Genet. 13, 1069-1079 (2004).
144. Langerholc, T. et al. Inhibitory properties of cystatin F and its localization in U937 promonocyte cells. FEBS J. 272, 1535-1545 (2005).
145. Abrahamson, M., Alvarez-Fernandez, M. & Nathanson, C. M. Cystatins. Biochem. Soc. Symp. 70, 179-199 (2003).